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Uric acid disposition during intermittent chemotherapy of pulmonary tuberculosis
was studied in 13 patients allocated to a thrice-weekly regimen containing pyrazina-
mide in addition to rifampicin, isoniazid and streptomycin and in 19 patients allo-
cated to a twice-weekly regimen of the same four drugs; the dosage of pyrazinamide
was 50 mg/kg in the former and 70 mg/kg in the latter. In the thrice-weekly series,
the mean serum uric acid concentration½ h before drug administration at 2 months
(5.5 mg/dl) was significantly higher (P< 0.001) than that on admission (3.2 mg/
dl); hyperuricaemia (>7 mg/dl) was observed in none of the patients on admission
and in 3 at 2 months. In the twice-weekly series, the two values (3.4 and3.1 mg/dl,
respectively) were similar, and none of the patients bad hyperuricaemia. The mean
concentrations 5 h after drug administration at 2 months were significantly higher
(P< 0.001) than those before drug administration in both the series (6.6 and 4.8
mg/dl, respectively), and hyperuricaemia was observed in 4 patients, all in the thrice
weekly series.
The incidence of arthralgia has been
reported to be high during treatment of
pulmonary tuberculosis patients with
regimens containing pyrazinamide which
had a daily phase followed by a twice-
weekly phase; and the onset in the great
majority of patients was during the daily
phase1,2. In a current clinical study, in-
termittent regimens containing pyrazi-
namide during an initial, intensive phase
of 2 months are being investigated. Since
there is circumstantial evidence impli-
cating altered disposition of uric acid
in the development of arthralgia in pa-
tients receiving pyrazinamide3,4, a de-
tailed investigation was undertaken to
study these alterations during intermit-
tent chemotherapy; this report presents
the findings.
Material & Methods
Treatment regimens: Patients with pul-
monary tuberculosis are being allocated
at random to one of the following two
regimens (during the initial intensive
phas  of 2 months) in a clinical study
currently in progress at our Centre.
RSHZ3 : Rifampicin (R), streptomycin
(S), isoniazid (H) and pyrazinamide (Z)
thrice weekly for 2 months.
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RSHZ2 : R, S, H and Z twice weekly for
2 months.
The dosages are : rifampicin 15
mg/kg body weight, streptomycin 0.75 g,
isoniazid 15 mg/kg, and pyrazinamide
50 mg/kg in the RSHZ3 regimen and 70
mg/kg in the RSHZ2 regimen.
The rate of urinary excretion (based
on a 1 h urine collection) and serum con-
centration of uric acid (at the mid-point
of the urine collection period) were de-
termined in 13 RSHZ3 and 19 RSHZ2
patients before the start of treatment and
before drug administration on the last
day of the initial intensive phase of treat-
ment, i.e., at 2 months (all the. patients
had received their penultimate dose of
drugs). These patients were then adminis-
tered their scheduled chemotherapy in-
clusive of pyrazinamide, and the rate of
urinary excretion, based on a 4½-5½ h
urine collection, and the serum concen-
tration of uric acid at 5 h were determined.
None of the patients was receiving any
analgesic at the time of the tests, and
they were not given beverages (such as
coffee or tea) containing methylated puri-
nes on the days of the test.
Uric acid concentrations in serum
and urine were determined by a phospho-
tungstate reduction method5, an  hyper-
uricaemia6,7 has been defined as a serum
concentration greater than 7 mg/dl.
The differences between the mean
values within each series were tested by
t test (paired), while analysis of co-vari-
ance (adjusting for pre-treatment differ-
ences) was employed for testing the differ-
ences in the mean values at 2 months
between the two series.
Results
The mean rates of urinary excretion
and the serum concentration of uric acid
before the start of treatment and at the
end of the initial intensive phase of treat-
ment are presented in the Table.
Table. Uric acid disposition during intermittent chemotherapy
(Data are mean ± SD)
Period of urine collection Rate of urinary excretionSerum concentrations
of uric acid (µg/min) of uric acid (mg/dl) at
mid-point of period
RSHZ3 RSHZ2 RSHZ3 RSHZ2
1 h prior to start of chemotherapy
At 2 months :
1 h prior to drug administration
4½ to 5½ h after drug administration
324 ± 201 378 ± 163 3.2 ± 1.0 3.l ± 1.3
442 ± 190 376 ± 112 5.5 ± 2.1 3.4 ± 1.2
214 ± 96 160 ± 53 6.6 ± 2.0 4.8 ± 1.2
RSHZ3 – Rifampicin, streptomycin, isoniazid and pyrazinamide thrice-weekly for 2 months (13 patients)
RSHZ2 – Rifampicin, streptomycin, isoniazid andpyrazinamidetwice-weekly for 2 months (19 patients)
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In the thrice-weekly series, the mean
rate of urinary excretion of uric acid
before drug administration at 2 months
(approximately 48 h after the previous
dose of drugs) was about 36 per cent
higher than that before start of treatment
(P=0.07), while in the twice-weekly
series (approximately 72 h after the pre-
vious dose of drugs), the 2 values were
similar. Administration of pyrazinamide
caused a significant decrease in the rate
of excretion (based on urine collected
over the period 4½- 5½ h) in both groups
of patients (P<0.01); the decrease was
of the order of 55 per cent in each. The
mean rate of excretion at 2 months ap-
peared to be higher in the thrice-weekly
series than in the twice-weekly series;
the difference before drug administration
was not significant (P=0.09), and that
after administration of drugs just attained
statistical significance (P=0.05).
The mean serum uric acid concentra-
tion about 4 h before drug administra-
tion at 2 months was 72 per cent higher
(P<0.001) than the pretreatment value
in the thrice-weekly series, while the 2
values were similar in the twice-weekly
series. The mean concentration 5 h after
drug administration was 20 per cent
high r in the thrice-weekly series and 40
per cent higher in the twice weekly series
than the respective mean values before
drug administration (P<0.001). The
mean concentrations in the thrice-weekly
serie  were higher than in the twice-weekly
seri s both before and after drug adminis-
tration at 2 months (62 and 38%, respec-
tive ; P<0.01, for both).
None of the patients in either group
had concentrations higher than the 7 mg/
dl before start of treatment (Fig.). At
2 months, hyperuricaemia was observed
Fig. Distribution of serum uric acid concentrations in 13 RSHZ3
and 19 RSHZ2 patients.
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in 3 of 13 RSHZ3 patients and in none
of the 19 RSHZ2 patients ½ h before
drug administration (P=0.06); the pro-
portions were 4 of 13 and none of 19,
respectively 5 h after drug administra-
tion (P=0.02).
Discussion
Pyrazinamide is metabolised to pyra-
zinoic acid by hepatic microsomal pyra-
zinamide deamidase8,9, and the latter
suppresses urinary excretion of uric acid
by inhibiting its tubular secretion9-l2.
This suppression is probably independent
of the dosage of pyrazinamide, as inves-
tigations undertaken earlier at our Centre
(unpublished data based on 20 patients)
have shown that the decrease in the rate
of excretion of uric acid (based on a
4½-5½ h urine collection after drug ad-
ministration) with a 70 mg/kg dose (44%)
was similar to that with a 35 mg/kg dose
(41%).
During daily treatment with regimens
containing pyrazinamide 35 mg/kg, uric
acid excretion is suppressed for a long
duration of time (> 12 h), but returns to
normal (pre-treatment) levels by about
24 h after drug administration13. Results
presented in this paper also show a marked
suppression in the urinary excretion of
uric acid initially during treatment with
intermittent regimens containing pyrazi-
namide 50 or 70 mg/kg; however, the
rate of excretion at approximately 48 h
after the previous dose of drugs (in the
thrice weekly series) is higher than that
on admission, while that at 72 h (in the
twice weekly series) is similar to the pre-
treatment value. This suggests that after
release of inhibition of uric acid excre-
tion, the urinary excretion rate exceeds
the normal rate for a period of time to
enable the system to eliminate the retain-
d uric acid. When this phase is over
(between 48 and 72 h), the excretion rate
returns to normal as is seen in the twice-
weekly series. These findings are consis-
tent with those of Ellard and Haslam12
who estimated that urinary excretion of
uric acid will be suppressed 80 per cent
of the time with daily regimens containing
pyraziaamide, 40-50 per cent of the time
with thrice-weekly regimens and only
30-40 per cent of the time with twice-
weekly regimens.
The mean serum uric acid concentra-
tion about ½ h before drug administra-
tio  2 months after start of treatment was
significantly higher than the pre-treat-
men  value in the thrice-weekly series,
while the difference between the two val-
ues was not significant in the twice-weekly
series. This suggests that the retained
uric acid is not completely eliminated
by 48 h, and that an interval of at least
3 days between successive doses is neces-
sary to enable the serum concentrations
to return to the pre-treatment levels.
Hyperuricaemia was observed in 3
(9%) of 32 patients who received inter-
mittent chemotherapy with regimens con-
taining pyrazinamide and rifampicin for
2 months. In contrast, serum concentra-
tions of greater than 7 mg/dl were obser-
ved n 65 per cent of 319 patients during
treatment with daily regimens containing
the two drugs for 2 months2. I  is there-
fore to be expected that arthralgia during
treatment with pyrazinamide would be
appreciably lower with intermittent re-
gim ns than with daily regimens.Si ce
hyperuricaemia during intermittent treat-
ment, either before or at 5 h after drug
administration, was not observed in the
twice-weekly series, it is also likely that
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Occurrence of arthralgia would be less
frequent in these patients than in those
receiving thrice-weekly treatment. Indeed,
preliminary findings in patients admitted
to the current clinical study indicate that
the incidence of arthralgia during the. ini-
tial intensive phase of 2 months is of
the order of 10-15 per cent with intermit-
tent regimens, while it was 34 per cent
during the same period in patients on
daily treatment2. There is also a sugges-
tion that arthralgia is more frequently
encountered among patients in the thrice-
weekly series than among those in the
twice-weekly series.
During daily treatment of pulmonary
tuberculosis with short-course regimens
containing pyrazinamide, it was observed
that the incidence of arthralgia was ap-
preciably less in patients who also re-
ceived rifampicin than in those who did
not1,2. Rifampicin has been shown to
enhance the urinary excretion of uric
acid13, and the serum concentrations of
uric acid during daily treatment have
been shown to be slightly but significantly
lower in patients who received this drug
than in those who did not2. B th the in-
termittent regimens employed in the pre-
sent study contain rifampicin in addition
to pyrazinamide, and uric acid disposi-
tion with intermittent non-rifampicin re-
gimens has therefore not been studied.
It is, however, possible that hyperuri-
caemia, and consequently arthralgia,
could be higher during treatment with
fully intermittent short-course regimens
which do not contain rifampicin than
with those which include this drug.
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